SCHEMBL282140

SCHEMBL282140

Fc1nc(F)c(Cl)c(F)c1Cl

nearest known ligand 0.35

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9513607 0.97 MEN1 (0.34) MEN1KMT2AGAA
SCHEMBL502245 0.87 MEN1 (0.37) MEN1KMT2AGAAMAPTHTT
SCHEMBL9787015 0.84
SCHEMBL9787166 0.81 MEN1 (0.32) MEN1KMT2AGAA
SCHEMBL10744284 0.80 MEN1 (0.37) MEN1KMT2AGAAMAPTHTT
Pyridine SCHEMBL10754731 0.80 TSHR (0.41) MEN1KMT2AGAA
SCHEMBL10870412 0.80 MEN1 (0.31) MEN1KMT2AGAAMAPTHTT
SCHEMBL8735002 0.80 CES2 (0.31)
SCHEMBL10871601 0.80 MEN1 (0.34) MEN1KMT2AGAA
SCHEMBL7028015 0.79 MEN1 (0.36) MEN1KMT2AGAAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113896679-B Synthesis method of key intermediate of pyrrole pyridine kinase inhibitor 合肥利夫生物科技有限公司 2024-03-01 CN claimed
US-11649232-B2 Synthetic dimeric cinchona alkaloids against cancer Ares Pharmaceuticals, LLC (US) 2023-05-16 US claimed
US-20220372029-A1 SYNTHETIC DIMERIC CINCHONA ALKALOIDS AGAINST CANCER Ares Pharmaceuticals, LLC (US) 2022-11-24 US claimed
CN-113896679-A Synthesis method of key intermediate of pyrrole pyridine kinase inhibitor 合肥利夫生物科技有限公司 2022-01-07 CN claimed
EP-3149020-A2 CHEMICALLY MODIFYING PEPTIDES The University of Durham (GB) 2017-04-05 EP claimed
EP-3149021-A1 CYCLISING PEPTIDES The University of Durham (GB) 2017-04-05 EP claimed
WO-2015181544-A2 CHEMICALLY MODIFYING PEPTIDES THE UNIVERSITY OF DURHAM (GB) 2015-12-03 WO claimed
WO-2015181545-A1 CYCLISING PEPTIDES THE UNIVERSITY OF DURHAM (GB) 2015-12-03 WO claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
WO-2000044724-A1 IMPROVED METHOD FOR THE PREPARATION OF 3,5-DICHLORO-2,4,6-TRIFLUOROPYRIDINE MAKHTESHIM CHEMICAL WORKS LTD. (IL) 2000-08-03 WO claimed
EP-0491688-A4 METHODS FOR ACTIVATING POLYMERIC CARRIERS AND COMPOSITIONS PREPARED THEREFROM FOR USE IN AFFINITY CHROMATOGRAPHY 1993-03-10 EP claimed
EP-0491688-A1 METHODS FOR ACTIVATING POLYMERIC CARRIERS AND COMPOSITIONS PREPARED THEREFROM FOR USE IN AFFINITY CHROMATOGRAPHY. BIOPROBE INT INC (US) 1992-07-01 EP claimed
WO-1991003257-A1 METHODS FOR ACTIVATING POLYMERIC CARRIERS AND COMPOSITIONS PREPARED THEREFROM FOR USE IN AFFINITY CHROMATOGRAPHY BIOPROBE INTERNATIONAL, INC. (US) 1991-03-21 WO claimed
US-4999432-A Heating and dechlorination of a chloropyridine DOWELANCO (US) 1991-03-12 US claimed
EP-0415498-A2 Fluorination with hydrogen fluoride DOWELANCO (US) 1991-03-06 EP claimed
US-4981961-A Chemically-stable chromatography adsorber; modifying nucleophilic polymers with pyridine bases BIOPROBE INTERNATIONAL, INC. (US) 1991-01-01 US claimed
EP-0270221-A1 Method of preparation of 3,5-dichloro-2,4,6-trifluoropyridine DOWELANCO (US) 1988-06-08 EP claimed
US-4746744-A Method of preparation of 3,5-dichloro-2,4,6-trifluoropyridine THE DOW CHEMICAL COMPANY (US) 1988-05-24 US claimed
EP-0192287-A2 Process for the preparation of fluorinated pyridines SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1986-08-27 EP claimed
US-4542221-A Exchanging fluorine for chlorine in a chlorinated pyridine with an alkali metal fluoride THE DOW CHEMICAL COMPANY (US) 1985-09-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649232-B2 Synthetic dimeric cinchona alkaloids against cancer BAD, MCL1, BCL9 MEN1 140/4885KMT2A 462/4885GAA 1063/4885
US-20220372029-A1 SYNTHETIC DIMERIC CINCHONA ALKALOIDS AGAINST CANCER BAD, MCL1, BCL9 MEN1 140/4885KMT2A 462/4885GAA 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.